Flevy Management Insights Case Study
Global Market Penetration Strategy for Pharma Company in Oncology
     Joseph Robinson    |    Business Resilience


Fortune 500 companies typically bring on global consulting firms, like McKinsey, BCG, Bain, Deloitte, and Accenture, or boutique consulting firms specializing in Business Resilience to thoroughly analyze their unique business challenges and competitive situations. These firms provide strategic recommendations based on consulting frameworks, subject matter expertise, benchmark data, KPIs, best practices, and other tools developed from past client work. We followed this management consulting approach for this case study.

TLDR A leading pharma company faced a 20% market share decline from competition and regulatory changes, worsened by slow drug development and supply chain challenges. By adopting Lean Startup and Risk Management Frameworks, it reduced drug development cycles by 30%, improved supply chain resilience, and increased market share by 15% in emerging markets, highlighting the importance of Strategic Planning and operational optimization.

Reading time: 9 minutes

Consider this scenario: A leading pharmaceutical company, specializing in oncology, faces significant challenges in maintaining business resilience amidst a rapidly evolving healthcare landscape.

The organization has experienced a 20% decline in market share over the past two years, primarily due to aggressive competition and regulatory changes. Internal challenges include slow drug development cycles and inefficiencies in supply chain management. The primary strategic objective of the organization is to enhance its global market penetration while streamlining operations and fostering innovation in drug development.



The organization, despite its strong reputation in oncology, is facing stagnation due to its slow response to market changes and internal operational inefficiencies. A deeper analysis may reveal that these challenges stem from a lack of agility in its R&D processes and a rigid supply chain that fails to adapt to market demands efficiently.

Industry Analysis

The pharmaceutical industry, especially within oncology, is characterized by high competition and rapid technological advancements. The entry of biosimilars and targeted therapies has intensified the competitive landscape, requiring traditional players to innovate continually.

Examining the primary forces driving the industry:

  • Internal Rivalry: The oncology sector sees intense competition, with numerous companies vying for market share through innovation and global expansion.
  • Supplier Power: Limited due to the high number of suppliers providing raw materials and services for drug manufacturing.
  • Buyer Power: Increasing, as healthcare providers and patients demand more effective and cost-efficient cancer treatments.
  • Threat of New Entrants: Moderately high, given the potential for breakthrough innovations in cancer treatment.
  • Threat of Substitutes: High, with the rapid development of alternative therapies such as immunotherapy and precision medicine.

Emergent trends in the industry include the shift towards personalized medicine, the growing importance of real-world evidence for drug approval, and the emphasis on cost-effectiveness. Major changes in industry dynamics include:

  • The rise of personalized medicine creates opportunities for developing targeted therapies but requires significant investment in genetic and biomarker research.
  • Incorporation of real-world evidence in drug development and approval processes offers the opportunity to accelerate time-to-market but poses challenges in data collection and analysis.
  • Increasing scrutiny on drug pricing and cost-effectiveness presents risks of pricing pressures but also opportunities for companies that can demonstrate clear patient benefits.

For a deeper analysis, take a look at these Industry Analysis best practices:

Strategic Analysis Model (Excel workbook)
Consolidation-Endgame Curve Framework (29-slide PowerPoint deck)
Porter's Five Forces (26-slide PowerPoint deck)
Market Entry Strategy Toolkit (109-slide PowerPoint deck)
4 Actions Framework (30-slide PowerPoint deck)
View additional Business Resilience best practices

Are you familiar with Flevy? We are you shortcut to immediate value.
Flevy provides business best practices—the same as those produced by top-tier consulting firms and used by Fortune 100 companies. Our best practice business frameworks, financial models, and templates are of the same caliber as those produced by top-tier management consulting firms, like McKinsey, BCG, Bain, Deloitte, and Accenture. Most were developed by seasoned executives and consultants with 20+ years of experience.

Trusted by over 10,000+ Client Organizations
Since 2012, we have provided best practices to over 10,000 businesses and organizations of all sizes, from startups and small businesses to the Fortune 100, in over 130 countries.
AT&T GE Cisco Intel IBM Coke Dell Toyota HP Nike Samsung Microsoft Astrazeneca JP Morgan KPMG Walgreens Walmart 3M Kaiser Oracle SAP Google E&Y Volvo Bosch Merck Fedex Shell Amgen Eli Lilly Roche AIG Abbott Amazon PwC T-Mobile Broadcom Bayer Pearson Titleist ConEd Pfizer NTT Data Schwab

Internal Assessment

The organization possesses strong capabilities in oncology research and a robust portfolio of cancer drugs, yet struggles with slow R&D processes and a rigid supply chain.

A PESTLE Analysis highlights the significant impact of regulatory changes, technological advancements, and economic fluctuations on the company's operations and market positioning. The evolving regulatory landscape and advancements in cancer treatment technologies present both challenges and opportunities for innovation and market expansion.

A Value Chain Analysis reveals inefficiencies in inbound logistics, operations, and outbound logistics, indicating potential areas for process optimization and cost reduction. Strengthening these areas could enhance the company's competitiveness and responsiveness to market demands.

A Distinctive Capabilities Analysis identifies the company's strong research capabilities and established market presence as key strengths. However, to maintain its competitive edge, the organization must improve its agility in research and development and enhance supply chain flexibility.

Strategic Initiatives

Based on the insights from the Industry Analysis and Internal Assessment, the management has decided to pursue the following strategic initiatives over the next 18 months :

  • Accelerate Drug Development Cycle: Streamline R&D processes to reduce time-to-market for new oncology drugs. This initiative aims to enhance the company's competitive edge by bringing innovative treatments to market more quickly. Streamlining R&D will involve adopting agile methodologies, investing in technology, and fostering closer collaboration with regulatory bodies. This will require resources in technology, talent development, and regulatory affairs expertise.
  • Strengthen Supply Chain Resilience: Overhaul supply chain management to improve flexibility and reduce vulnerabilities to external shocks. This initiative will create value by ensuring continuous drug availability, reducing costs, and enhancing customer satisfaction. Implementing advanced supply chain planning tools and diversifying the supplier base are critical steps. Resources needed include technology investment and supply chain management expertise.
  • Expand into Emerging Markets: Identify and enter high-growth emerging markets, focusing on regions with increasing incidence of cancer and healthcare spending. This initiative aims to increase global market share and revenue. The source of value creation comes from tapping into new patient populations and expanding the company's global footprint. It will require investment in market research, local partnerships, and regulatory compliance.

Business Resilience Implementation KPIs

KPIS are crucial throughout the implementation process. They provide quantifiable checkpoints to validate the alignment of operational activities with our strategic goals, ensuring that execution is not just activity-driven, but results-oriented. Further, these KPIs act as early indicators of progress or deviation, enabling agile decision-making and course correction if needed.


If you cannot measure it, you cannot improve it.
     – Lord Kelvin

  • Time-to-Market for New Drugs: Measures the effectiveness of streamlined R&D processes in accelerating drug development.
  • Supply Chain Disruption Recovery Time: Tracks the resilience of the supply chain in responding to disruptions.
  • Market Share Growth in Emerging Markets: Indicates the success of market expansion strategies in new regions.

These KPIs provide insights into the efficiency of R&D processes, the robustness of the supply chain, and the effectiveness of market expansion strategies. Monitoring these metrics will enable the company to adjust its strategies in response to performance and market developments.

For more KPIs, take a look at the Flevy KPI Library, one of the most comprehensive databases of KPIs available. Having a centralized library of KPIs saves you significant time and effort in researching and developing metrics, allowing you to focus more on analysis, implementation of strategies, and other more value-added activities.

Learn more about Flevy KPI Library KPI Management Performance Management Balanced Scorecard

Business Resilience Best Practices

To improve the effectiveness of implementation, we can leverage best practice documents in Business Resilience. These resources below were developed by management consulting firms and Business Resilience subject matter experts.

Business Resilience Deliverables

These are a selection of deliverables across all the strategic initiatives.

  • R&D Process Optimization Plan (PPT)
  • Supply Chain Resilience Report (PPT)
  • Emerging Market Entry Strategy (PPT)
  • Financial Impact Model of Strategic Initiatives (Excel)

Explore more Business Resilience deliverables

Accelerate Drug Development Cycle

The organization adopted the Lean Startup methodology, widely recognized for its effectiveness in accelerating product development and innovation. The Lean Startup approach emphasizes rapid iterations, validated learning, and a "build-measure-learn" feedback loop. It was particularly useful for this strategic initiative because it allowed the pharmaceutical company to streamline its R&D processes, thereby reducing time-to-market for new oncology drugs. The team followed this process:

  • Initiated small-scale, rapid clinical trials to test hypotheses about new drug formulations and their effectiveness.
  • Implemented a continuous feedback loop with key stakeholders, including regulatory bodies, to ensure that the development process aligned with compliance requirements and market needs.
  • Adopted a flexible approach to R&D, allowing for quick pivots based on trial outcomes and feedback, thereby minimizing wasted resources on less promising drug candidates.

The implementation of the Lean Startup methodology resulted in a significant reduction in the drug development cycle. The organization was able to bring several new oncology drugs to market faster than previously possible, enhancing its competitive position and responding more rapidly to patient needs.

Strengthen Supply Chain Resilience

To enhance its supply chain resilience, the company utilized the Risk Management Framework (RMF). The RMF is a systematic process for identifying, assessing, and mitigating risks. It proved invaluable for this strategic initiative by providing a structured approach to identifying vulnerabilities within the supply chain and implementing measures to mitigate these risks. The organization took the following steps:

  • Conducted a comprehensive risk assessment to identify potential vulnerabilities and disruptions within the supply chain, including supplier risks, logistical challenges, and geopolitical factors.
  • Developed and implemented risk mitigation strategies, such as diversifying suppliers, establishing strategic stockpiles, and investing in predictive analytics to anticipate and respond to potential disruptions.
  • Regularly reviewed and updated the risk management plan to adapt to changing market conditions and emerging risks.

The application of the Risk Management Framework enabled the company to significantly improve the resilience of its supply chain. This led to a more robust and flexible supply chain capable of withstanding various disruptions, ensuring continuous drug availability and reducing costs associated with supply chain inefficiencies.

Expand into Emerging Markets

The Ansoff Matrix was employed to guide the company's expansion into emerging markets. This strategic planning tool helps organizations determine their product and market growth strategy by focusing on four different growth strategies: market penetration, market development, product development, and diversification. The Ansoff Matrix was instrumental for this initiative as it provided a clear framework for identifying opportunities for growth in new geographical markets. Following this approach, the organization:

  • Identified high-growth emerging markets with an increasing incidence of cancer and healthcare spending through extensive market research.
  • Evaluated the potential for existing oncology drugs in these new markets, considering regulatory environments, competitive landscapes, and patient needs.
  • Developed tailored market entry strategies for each identified market, including partnerships with local healthcare providers, regulatory compliance strategies, and marketing plans to build brand awareness.

By implementing the Ansoff Matrix framework, the pharmaceutical company successfully entered several emerging markets, resulting in increased global market share and revenue. This strategic expansion not only diversified the company's geographical presence but also mitigated risks associated with operating in a limited number of markets.

Additional Resources Relevant to Business Resilience

Here are additional best practices relevant to Business Resilience from the Flevy Marketplace.

Did you know?
The average daily rate of a McKinsey consultant is $6,625 (not including expenses). The average price of a Flevy document is $65.

Key Findings and Results

Here is a summary of the key results of this case study:

  • Reduced drug development cycle by 30% through the adoption of the Lean Startup methodology, enabling faster market entry for new oncology drugs.
  • Improved supply chain resilience, reducing disruption recovery time by 40% by implementing the Risk Management Framework (RMF).
  • Achieved a 15% growth in market share in targeted emerging markets by applying the Ansoff Matrix for strategic expansion.
  • Streamlined R&D processes and supply chain management led to a 20% reduction in operational costs.
  • Launched three new oncology drugs in emerging markets within the first year, surpassing initial projections.

The strategic initiatives undertaken by the pharmaceutical company have yielded significant positive outcomes, notably in reducing the drug development cycle, enhancing supply chain resilience, and expanding into emerging markets. The adoption of the Lean Startup methodology and the Risk Management Framework (RMF) has not only accelerated the introduction of new drugs to the market but also fortified the supply chain against disruptions. The successful entry into emerging markets, guided by the Ansoff Matrix, has increased global market share and revenue, demonstrating the effectiveness of the company's strategic planning and execution. However, while these results are commendable, the 20% reduction in operational costs, though substantial, suggests there may still be inefficiencies within the company's operations that could be further optimized. Additionally, the focus on emerging markets, while successful, may have diverted resources from other potential areas of growth or innovation. An alternative strategy could have included a greater emphasis on diversifying the drug portfolio to include non-oncology areas, potentially spreading risk and opening new revenue streams.

For next steps, it is recommended that the company continues to refine its operational efficiencies, particularly in areas not directly impacted by the recent initiatives. Exploring opportunities for portfolio diversification could mitigate risks associated with over-reliance on oncology. Additionally, investing in digital transformation and advanced analytics could further streamline R&D and supply chain processes, enhancing agility and responsiveness to market changes. Finally, a continuous review of strategic initiatives against performance metrics should be instituted to ensure sustained growth and competitiveness in the dynamic pharmaceutical industry.

Source: Global Market Penetration Strategy for Pharma Company in Oncology, Flevy Management Insights, 2024

Flevy is the world's largest knowledge base of best practices.


Leverage the Experience of Experts.

Find documents of the same caliber as those used by top-tier consulting firms, like McKinsey, BCG, Bain, Deloitte, Accenture.

Download Immediately and Use.

Our PowerPoint presentations, Excel workbooks, and Word documents are completely customizable, including rebrandable.

Save Time, Effort, and Money.

Save yourself and your employees countless hours. Use that time to work on more value-added and fulfilling activities.




Read Customer Testimonials




Additional Flevy Management Insights

Business Resilience Reinforcement for Forestry & Paper Products Firm

Scenario: A forestry and paper products company in the Pacific Northwest is grappling with the challenge of maintaining operational continuity amidst rising environmental and market volatility.

Read Full Case Study

Digital Transformation Strategy for Boutique Animation Studio

Scenario: A boutique animation studio, recognized for its creative storytelling and unique animation styles, faces challenges in maintaining business resilience amidst an increasingly competitive and technology-driven entertainment industry.

Read Full Case Study

Business Resilience Reinforcement in Retail

Scenario: A retail company specializing in high-end electronics has been facing increased disruptions due to supply chain volatility and rapid shifts in consumer behavior.

Read Full Case Study

Artisanal Mining Strategy Transformation for Sustainable Impact

Scenario: An artisanal mining cooperative in Sub-Saharan Africa is facing significant strategic challenges impacting its business resilience.

Read Full Case Study

Omni-Channel Strategy for Independent Bookstore in Entertainment Niche

Scenario: An independent bookstore operating in the competitive entertainment niche is facing challenges related to business resilience as it combats a 20% decline in foot traffic and a 30% decrease in in-store sales over the past two years.

Read Full Case Study

Content Strategy Redefinition for Independent Film Production Studio

Scenario: A niche independent film production studio, specializing in documentary content, is struggling with maintaining business resilience in the face of rapidly changing media consumption habits and a highly competitive market.

Read Full Case Study

Plastics Manufacturing Operational Resilience Strategy Transformation

Scenario: A mid-size plastics manufacturing company based in North America faces a significant challenge in maintaining organizational resilience amid fluctuating raw material costs and stringent environmental regulations.

Read Full Case Study

Live Events Digital Transformation Strategy for Boutique Music Festivals

Scenario: A boutique music festival organization is seeking to enhance its business resilience in a highly competitive and dynamic market environment.

Read Full Case Study

Operational Excellence Strategy for Apparel Manufacturing in Competitive Markets

Scenario: A boutique apparel manufacturer, specializing in sustainable clothing, is confronting challenges related to business resilience in a volatile market.

Read Full Case Study

Supply Chain Optimization Strategy for Wholesale Electronic Markets

Scenario: A mid-size wholesaler in the electronic markets is grappling with challenges related to business resilience.

Read Full Case Study

Operational Excellence Strategy for Insurance Carrier in Competitive Market

Scenario: An established insurance carrier is facing challenges in sustaining business resilience amidst a highly competitive and evolving market landscape.

Read Full Case Study

Strengthening Resilience in Transportation Equipment Manufacturing Amid Operational Disruptions

Scenario: A transportation equipment manufacturer implemented a strategic Business Resilience framework to address significant operational disruptions.

Read Full Case Study

Download our FREE Strategy & Transformation Framework Templates

Download our free compilation of 50+ Strategy & Transformation slides and templates. Frameworks include McKinsey 7-S Strategy Model, Balanced Scorecard, Disruptive Innovation, BCG Experience Curve, and many more.